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Dietao-estrogens are believed to exert their
estrogenic or antiestrogenic (chemopreven-
dive) action in estrogen responsive cells by
iteracting ~with the festrgen reeptor (ER).
The p s tudy undertaen to evalu-
ate adir roleofERin estrgic orantie-
strogenic activities ofthreedietay eso
(coumestrol, genistein and tearalenone).
HeLadcells were tiently -transfected
with an expression sector for ER and an
en-responsie reporter gene construct.
Coumestrol, gnstein, and zearalenone all
increased the activity of the reporter gene,
only inthe presence:oftheER, an-the acti-
vationa blocks width the ER antagonist
ICI 164,384, de r an ER-specific,
agonist response. In addition, in MCF-7
cells. coumestrol and.elenone icased
the expression ofe:e estrogen-rsponsie
pS2.gne. Coumstrlji and giin ihibit-
ed tho purified estrogen-specific 17FA-
hydroxysteroid oxidorducta enzyme and
the conversion of-estne to 17C-estradol in
T-47D cells, whiph contain this enzyme.
However, they did not inhibit theetone
induced proliferation ofT-47D cells. In
conclusion, coumestrol, genistin, and rear-
alenone areallpotentestrogens-inviHe and:i
te si th Rdiaend oie n.
Our findings give no evidence to support
the idea that these compounds act as antie-
strogens through competition for the bind-
Lag site ofER or:b inhibition the con-
vrinofestroe o 17-estradiol in breast
cancerclls, since thi effectwas nulified by
their agonist action on cell proliferation.
Therefre, their eted emp veni
action estrogen-related cars must be
mediaed through other mch- nisms. Key
womr uantiestrogens, breast cancer, estrogen
metabolism, estrogen receptor, gene expres-
sion, phytoestrogens. Environ Health
Peripct.102:572-578 (1994)
Human diets are known to contain various
plant-derived nonsteroidal weakly estro-
genic compounds (phytoestrogens).
Structurally, they are divided into three
classes: isoflavonoids, coumestans, and
mammalian lignans. Isoflavonoids (e.g.,
biochanin Aand genistein) and coumestans
(coumestrol) are formed in numerous edi-
ble plants, especially in soy and other legu-
minous plants. Mammalian lignans (e.g.,
enterolactone and enterodiol) are mainly
derived from unrefined grain as precursors,
which are activated by intestinal bacteria.
Trace amounts of estrogenic mycotoxins
(e.g., zearalenone) are also found in human
diets. Structurally, zearalenone is resorcylic
acid lactone. A synthetic derivative ofzear-
alenone, zeranol, has been used as a hor-
monal substitute growth promoter in cat-
tle. The chemical structures ofcoumestrol,
genistein, and zearalenone are shown in
Figure 1.
Phytoestrogens may be excreted in
amounts hormonally comparable to the
endogenous steroidal estrogens (1). The
intake of dietary estrogens is significantly
higher in countries where the incidence of
breast and prostate cancers is low, suggest-
ing that they may act as chemopreventive
agents (1). The chemopreventive effect of
dietary soy which is rich in phytoestrogens
has recently been demonstrated on the
development of estrogen-dependent mam-
mary tumors (dimethylbenzanthracene-
and nitrosomethylurea-induced mammary
tumors in rats) (2). These compounds may
also account for the soy-effect seen as a
delayed development ofdysplastic changes
in the prostate of neonatally estrogenized
mice (3).
Dietary estrogens are believed to exert
their estrogenic or antiestrogenic (chemo-
preventive) action in estrogen responsive
cells by interacting with the specific intra-
cellular estrogen receptor (ER). In agree-
ment with this, the compounds (coume-
strol, genistein, and zearalenone) which are
the most active biologically (e.g., enhance
the proliferation of estrogen-responsive
tumor cells), also have high binding affini-
ties for ER (4) and have been shown to
exert estrogenic activity in vitro (5). To
exert antiestrogenic activity, it is postulated
that at proper concentrations, the phytoe-
strogens could compete for the same recep-
tor sites, displace endogenous estrogens
from receptor sites and block the action of
the hormonally more potent, endogenous
estrogens. In addition to acting through
the ER, other factors, such as inhibition of
tyrosine protein kinase, inhibition ofDNA
topoisomerase, inhibition of angiogenesis,
stimulation ofsex hormone binding globu-
lin, and suppression ofgrowth ofboth ER
positive and negative cancer cells, may be
operative in mediating the influence of
dietaryestrogens (6-JO).
The present study was undertaken to
provide direct support for the role of ER
in estrogenic and antiestrogenic action of
dietary estrogens (coumestrol, genistein,
biochanin A, zearalenone, and zeranol).
Their capability to interact with ER and
exert a specific, ER-mediated response was
studied in HeLa cells, which were tran-
siently co-transfected with an expression
vector for ER and an estrogen-responsive
chloramphenicol acetyl transferase (CAT)
reporter construct. In addition, the judge-
ment of their estrogenicity was based on
the proliferative response of two ER-posi-
tive breast cancer cell lines, MCF-7 and T-
47D cells, and the expression ofestrogen-
responsive gene, pS2, in MCF-7 cells.
Antiestrogenicity was analyzed in MCF-7
and T-47D cells by testing the prolifera-
tive response to the phytoestrogens in the
presence of 17g-estradiol or estrone and
the inhibition of 17g-reduction of estrone
by the estrogen-specific 17f-hydroxy-
steroid oxidoreductase, an enzyme which
Figure 1. Chemical structures of coumestrol,
genistein, and zearalenone.
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has been reported to be an indicator and
possible regulator of estrogen action in
breast tissue (13).
Materials and Methods
All reference steroids were purchased from
Steraloids, Inc. (Wilton, New Hampshire).
Stock cultures ofMCF-7 cells were grown
in Dulbecco's modified Eagle medium
(DMEM; Gibco BRL, Gaithersburg,
Maryland) supplemented with 5% fetal
bovine serum (FBS; Gibco BRL), insulin
(from bovine pancreas, 10 pg/ml; Sigma,
St. Louis, Missouri) and 17g-estradiol (1
nM; Sigma). For T-47D cells DMEM was
supplemented with 10% FBS and insulin
(7.5 pg/ml).
Cell Proliferation Experiments
For MCF-7 cell proliferation experiments,
phenol red-free DMEM (Sigma) supple-
mented with 5% dextran charcoal stripped
FBS, insulin (10 ug/ml) and antibiotics
(penicillin 100 U/ml and streptomycin
100 pg/ml) was used. The stock cultures
were harvested by trypsinization, resus-
pended with medium, and seeded on 96-
well culture plates at 2000 cells/well. The
test compounds 17f9-estradiol, estrone
(Sigma), coumestrol (Eastman Kodak,
Rochester, New York), genistein (Gibco
BRL), biochanin A (Sigma), zearalenone
(Sigma) and zeranol (International
Minerals and Chemical Corporation, Terre
Haute, Indiana) were dissolved in ethanol,
diluted with medium and added to culture
medium with final concentration of
ethanol of0.1%. The test compounds were
added at day 2 and the cell proliferation
assay was performed at day 9. For antie-
strogen experiments, the test compounds
were added 1 hr before estradiol. The
media which included the test compounds
was changed every otherday.
Cell proliferation was quantified by
colorimetric MTT assay. The use and
validity of the MTT assay in MCF-7 cells
is described by Martikainen et al. (14). We
added 30 pl of MTT (thiazolyl blue;
Sigma) solution (5 mg/ml in phosphate
buffered saline) to culture wells and incu-
bated them for 4 hr. The media was
removed and insoluble formazan (convert-
ed by viable cells from MTT) was solubi-
lized by adding 100 pl of dimethylsulfox-
ide per well. The absorbance ofconverted
dye was measured at a wavelength of 540
nm by a plate reader (Labsystems
Multiskan, Eflab OY, Helsinki, Finland).
Each culture plate had its own control (no
hormone), and the values (mean of one
row of eight wells) are expressed as per-
centages ofthe mean ofcontrol (16wells).
For T-47D cell proliferation experi-
ments, we used phenol red-free DMEM
with 10% dextran charcoal stripped FBS,
insulin (7.5 pg/ml) and antibiotics as
above. The stock cultures were harvested
by trypsinization, resuspended with medi-
um, and seeded on culture dishes (3 cm
diameter). Cells were allowed to attach
overnight, the media was changed, and the
test compounds were added as above. The
medium plus test compounds was changed
every other day. At day 7, cells were count-
ed in a Coulter counter.
Measurement of17fi-Hydroxy-
steroid OxidoreductaseActivity
The capability of dietary estrogens to
inhibit the estrogen-specific 17l3-hydroxy-
steroid oxidoreductase type I (E.C.
1.1.1.62) was tested by using the enzyme
purified from human placenta (12). An
aliquot of the purified enzyme in 15 mM
phosphate buffer, pH 7.4 with 2 mM
DTT, 1 mM EDTA, 1 mM PMSF, and
10% glycerol was preincubated with the
NADPH-generating system (50 pl 4 mM
NADP, 50 pl glucose-6-phosphate, 50 pl
glucose-6-phosphate dehydrogenase, 50
U/ml) in a final volume of 250 pl with
dietary estrogen (final concentration 1.2
pM) for 20 min. Thereafter, 3H-estrone
was added to the incubation medium to
give the final concentration of 0.72 pM.
Incubation was continued for 2 hr and
stopped by adding cold carriers (179-estra-
diol and estrone).
The steroids were extracted twice with
3 ml ofmethylene chloride. The combined
methylene chloride solutions were dried
over sodium sulfate and evaporated to dry-
ness under nitrogen. Extracted steroids
were dissolved in absolute ethanol, and
ethanol solutions were filtered and evapo-
rated. The residue was dissolved in 50 pl of
acetonitrile before HPLC run. The steroids
were separated and determined with
HPLC. The column system consisted ofa
guard column followed by a C 18 150 x
3.9 mm ID analytical column (Techopak
C18 HPLC Techonology, Weillington
House, Cheshire, UK). The mobile phase
was acetonitrile/water (35/65). Retention
times for estrone, 1713-estradiol, 16a-177f-
estriol, 2-OH-estradiol, 2-OH-estrone, 4-
OH-17f-estradiol, 4-OH-estrone, andros-
tenedione, and testosterone were 12.2, 9.8,
2.4, 4.9, 6.3, 5.4, 7.3, 13.0, and 10.8 min,
respectively. For inline detection of
radioactive metabolites, the eluent of the
HPLC column was continuously mixed
with liquid scintillant and then monitored
with inline radioactivity detector (Beta-
Flow, Pharmacia/LKB/Wallac, Turku,
Finland). Separation and quantification of
3H-labelled steroids have been described in
detail earlier (16). Relative velocities were
calculated for each compound.
The type of enzyme inhibition was
determined with a graphical method
according to Dixon (17). The reaction
velocities were determined with a series
inhibitor concentrations (1.2 nM to 0.12
pM) and with two substrate concentrations
(0.24 and 0.72 pM). Straight lines were
obtained on plotting 1/vversus i. The point
ofintersection ofthe two lines gave -KG.
The 17f-oxidoreductase activity of the
MCF-7 cells was assessed by determining
the ability of intact monolayers to convert
added 3H-estrone to 3H-estradiol (13,18).
For each experiment, MCF-7 cells were
harvested by trypsinization and seeded at a
concentration of 2 x 105 cells per culture
dish (60 x 15 mm). The cells were grown
for 5 days in 5 ml of the DMEM with
phenol red, supplemented with 5% FBS, 1
nM 17l-estradiol, and insulin (10 pg/ml).
The medium was changed every other day.
On day 5 of culture, the growth medium
was removed and the test compound was
added in 3 ml of phenol red-free DMEM
without serum or hormones. Control cul-
tures were run in parallel without the test
compound. After the preincubation with
the test compound for 1 hr, 3H-estrone (2
nM) was added to each dish, which were
then incubated for 4 to 24 hr. The number
of cells in each dish was determined by
counting released nuclei with a Coulter
counter.
In addition to interconversion of
estrone and estradiol, no other metabolites
(173-estradiol, 16a-179-estriol, 2-
hydroxy- or 4-hydroxyl derivatives of
estrone or estradiol) were formed under
conditions used for the assay of estradiol
17g-oxidoreductase activity.
Transfection ofHeLaCellswith Estro-
gen Receptor and Expression ofpS2
The estrogen-responsive reporter vector,
ERET81CAT, and the pRSV vector con-
taining the mouse ER cDNA (without the
neomycin resistance cassette) was con-
structed as previously described (19). The
HeLa cells were cotransfected with these
two vectors, +ER, or with only the
ERET81CAT reporter vector, -ER, to test
the ER-mediated estrogenic activity ofthe
phytoestrogens. The HeLa cells were
grown in phenol red-free DMEM/F12
medium (Sigma) supplemented with 5%
FBS and penicillin-streptomycin. Cells
were harvested by trypsinzation and mixed
with the ERET81CAT DNA, 70 pg/ml,
and the pRSV-ER DNA, 10 pg/ml, or
ERET81CAT only, 80 pg/ml. The cells
were electroporated at 960 pFD, 0.4 kV in
0.8 ml ofcells. Cells were then pooled and
plated on fibronectin treated plates in
DMEM/F12 plus insulin-transferrin-sodi-
um selenite (Sigma). Four hours after
transfection, the serum-free medium was
replaced and 1 nM 17g-estradiol (E2) or
varying concentrations ofthe dietary estro-
Volume 102, Number 6-7, June-July 1994 573gens were added as indicated. For incuba-
tion with the estrogen antagonist ICI
164,384 (ICI), the cells were pretreated for
1 hr with 100 nM ICI before co-incubat-
ing with the other hormones (20).
Triplicate samples for each hormone con-
centration were harvested at 28 hr after
transfection; the cells were harvested in
lysis buffer and then assayed for CAT
(chloramphenicol acetyltransferase) protein
with the CAT-ELISA kit (Boehringer
Mannheim, Indianapolis, Indiana) accord-
ing to the manufacturer's instructions.
CAT levels were standardized to total cel-
lular protein levels, measured by the BCA
protein assay reagent (Pierce, Rockford,
Illinois). Fold stimulation was calculated
from the induction over basal CAT levels
(vehicle only) within each transfection.
To determine expression ofpS2 in
MCF-7 cells, the stock cultures were har-
vested by trypsinization, resuspended with
medium and seeded on 6-cm diameter cul-
ture dishes at 200,000 cells/dish. After 4
days in culture, the media was changed to
serum-free and phenol red-free DMEM
with varying concentrations of17g-estradi-
ol (E2), coumestrol, genistein, or zear-
alenone. After 24 hr. the cells were harvest-
ed with guanidinium thiocyanate, and the
RNA was extracted with single-step
method (21). The expression ofpS2 gene
was studied by Northern blot technique as
described by Dubik and Shiu (22).
Data were analyzed using ANOVA and
Tukey's test on a BMDP 7D computer
program.
Results
]Effects ofDietaryEstrogens on Cell
Proliferation
Proliferation of MCF7 cells was analyzed
with the various dietary estrogens. The data
in Figure 2 show that coumestrol, genistein,
biochanin A, zearalenone, and zeranol all
significantly enhanced the proliferation of
MCF-7 cells. The response was dose depen-
dent in each case, and no inhibition was
seen at the concentrations of 1 pM or less.
Coumestrol, zearalenone, and zeranol were
potent at 10 pM while higher concentra-
tions (more than 1 nM) were needed to
show a significant estrogenic activity by
genistein or biochanin A. For comparison
with the dietary estrogen responses, the dose
dependency ofMCF-7 cell proliferation on
17B-estradiol and estrone is shown in Figure
3. The stimulation became significant at 10
pM concentration and reached its maxi-
mum at 1 nM concentration of17f1-estradi-
ol. Considerably higher concentrations of
estrone were needed to get a significant
stimulation.
MCF-7 cell proliferation was analyzed
for these same compounds in the presence
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Figure 2. Effect of (A) coumnestrol, (B) genistein,
(C) biochanin A, (0) zeralenone, and (E) zeranol
on the proliferation of MCF-7 cells. Dashed lines
indicate the control level (= 100%), and the dot-
ted lines indicate the effect of 17g-estradiol at
the concentration of 1 nM. Each value (U) is the
mean ± SD (n = 8-12 per each concentration
tested). (*,**) Significantly different from control
(p<0.05, p<0.01, respectively).
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Figure 3. Effect of (A) estradiol and (B) estrone on the proliferation of MCF-7 cells. Dashed lines indicate
the control level (= 100%), and the dotted line in panel B indicates the effect of 17B-estradiol at the con-
centration of 1 nM. Each value (-) is the mean ± SD (n = 8-12 per each concentration tested). (*,**)
Significantly differentfrom control (p<0.05, p<0.01, respectively).
of 10 pM 17f3-estradiol, a concentration
which results in submaximal stimulation,
to test these compounds for antiestrogenic
activity. None of the tested dietary estro-
gens, at concentrations below 10 nM,
reduced the rate of cell proliferation. On
the contrary, coumestrol, biochanin A,
zearalenone, and zeranol all had additive
effects with 17f3-estradiol (Fig. 4). A simi-
lar additive effect could not be demonstrat-
ed with genistein at any tested concentra-
tion. In contrast, genistein slightly reduced
the rate of the cell proliferation at the 1
and 10 pM concentrations. However, this
effect was not statistically significant.
MCF-7 proliferation was also tested with
these compounds in the presence of 1 nM
estradiol, which is the lowest concentration
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Figure 4. Effect of (A) coumnestrol, (B) genistein,
(C) biochanin A, (0) zeralenone, and (E) zeranol
on the proliferation of MCF-7 cells in the pres-
ence of 17g-estradiol. Dashed lines indicate the
control level (= 100%), and the dotted lines indi-
cate the effect of estradiol atthe concentration of
10 pM. Each value (U) is the mean ± SD (n = 8-12
per each concentration tested). (*,**)
Significantly different from control (p <0.05, p
<0.01, respectively); (.,..*) significantly different
from estradiol-treated group (p <0.05, p <0.01,
respectively).
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Figure 5. Effect of dietary estrogens on the expression of pS2 gene in MCF-7 cells. Lanes were exposed
to the following compounds atthe indicated concentrations; (1) control; (2) estradiol, 0.1 pM; (3) estradi-
ol, 1 nM; (4) estradiol 10 pM; (5) coumestrol, 0.1 pM; (6) coumestrol, 1 nM; (7) coumestrol, 10 pM; (8)
genistein, 0.1 pM; (9) genistein, 1 nM; (10) zeralenone, 0.1 pM; (11) zeralenone, 1 nM; (12) zeralenone, 10
PM; (13) zeranol, 0.1 pM; (14) zeranol, 1 nM; (15) zeranol, 10 pM. Ethidium bromide staining (used as a
control for equal loading) ofthe corresponding lanes is shown in the bottom panel.
to give maximal stimulation of prolifera-
tion. As with the 10 pM estradiol concen-
tration, no inhibition ofcell growth by the
phytoestrogens was observed (data not
shown).
Expression ofpS2Gene
The expression ofpS2, which is an estro-
gen-regulated gene and hormonally
responsive in breast cancer cells, was ana-
lyzed for stimulation by the compounds.
Estradiol was stimulatory at 1 and 100 nM
(Fig. 5). Coumestrol and zearalenone also
demonstrated an increase inpS2expression
at the concentration of 100 nM, while zer-
anol was active at 1 nM (Fig. 5). Genistein
had no effect at concentrations of 1 and
100 nM.
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Figure 6. Estrogen receptor (ER)-dependent chlo-
ramphenicol acetyltransferase (CAT) induction by
three dietary estrogens. Fold stimulation of CAT
protein levels was determined from basal CAT
levels in the transfected HeLa cells (vehicle only).
The concentration of 17f9-estradiol was 1 nM; 1DQ.
nM of genistein, coumestrol, zearalenone, and ICl
164,384 (IC) were added. HeLa cells cotransfect-
ed with the ERET81 CAT and pRSV-ER vectors
were designated as +ER. Cells transfected with
ERET81CAT alone are designated -ER. The data
represent the means ± SE. Values from +ER sam-
ples were determined from at least three sepa-
rate transfections, except for coumnestrol which
was done in duplicate experiments.
Transactivation ofEstrogen-respon-
sive Gene
At 100 nM, coumnestrol, genestein, and
zearalenone were able to increase the levels
of CAT protein over basal CAT levels in
HeLa cells co-transfected with the mouse
ER and an estrogen-responsive CAT
reporter gene (Fig. 6). In addition, 1 nM
of zeranol produced the maximal CAT
induction of 103.4 ± 10.4-fold stimula-
tion, whereas 2 1iM biochanin A was
required to achieve the 7.4 ± 0.4-fold
increase over untreated CAT levels. In
comparison with maximal 17g-estradiol-
induction (1 nM), coumnestrol (100 nM)
produced an equivalent fold stimulation,
however, both zeranol (1 nM) and zear-
alenone (100 nM) exceeded 17f9-estradi-
ol-induced activation. To ensure that the
estrogenic activity of these compounds
was directly mediated by the ER, the
transfected cells were coincubated with
the estrogen antagonist ICI 164,384 (100
nM) and the dietary estrogens. No induc-
tion of CAT was observed with 100 nM
coumnestrol, 100 nM genistein, and 100
nM zearalenone (Fig. 6) as well as with 1
nM zeranol (0.94 ± 0.47). The activity of
these phytoestrogens was also tested in
HeLa cells transfected with the estrogen-
responsive CAT vector, but not with the
ER. No stimulation was detected with
estradiol, coumnestrol, genistein, and zear-
alenone (Fig. 6) or zeranol and biochanin
A (data not shown). Therefore, the ER is
required for transcriptional activation of
CAT by all ofthese dietary estrogens.
Volume 102, Number 6-7, June-July 1994
pS2-
i...: ::,
1-6
575Table 1. Effect of dietary estrogens and triphenylethylene antiestrogens (tamoxifen, toremifene, and 4-
OH-toremifene) on the NADPH-dependent conversion of3H-estrone (0.72pM)to 3H-estradiol in vitroa
Inhibitor Concentration (pM) N Relative velocity
Coumestrol 1.2 6 18.8 ± 7.3
0.12 11 49.0 ± 15.4
12 8 75.6 ± 27.3
1.2 6 106.0±39.6
Genistein 1.2 10 62.8 ± 29.9
0.12 5 90.6±38.2
Biochanin A 1.2 8 91.3 ± 28.2
Zearalenone 1.2 12 84.6± 31.5
Tamoxifen 1.2 4 86.8 ± 8.1
Toremifene 1.2 7 92.1 ± 24.9
4-OH-Toremifene 1.2 7 91.3 ± 31.6
NValues are the means ± SD. Relative velocityfor contr
Inhibition of17B-.Estradiol
OxidoreductaseActivity
Even though only agonist activity was
observed in the transfection, expression,
and cell proliferation studies, we consid-
ered that dietary estrogens might act as
antiestrogens through an alternative mech-
anism, other than through the ER, by
inhibiting the 171f-estradiol oxidoreductase
enzyme. 17g-estradiol oxidoreductase is
the enzyme responsible for the 17g-reduc-
tion of estrone to estradiol and has been
reported to be an indicator and possible
regulator ofestrogen action in breast tissue
(13). The capability ofdietary estrogens to
inhibit the estrogen-specific 17f;-hydroxys-
teroid oxidoreductase type I (E.C.
1.1.1.62) was tested by using the enzyme
purified from human placenta. At a con-
centration of 12 nM, coumestrol signifi-
candy inhibited the enzyme, while consid-
erably higher concentrations were needed
to show inhibition with genistein (Table
1). Zearalenone was inactive at the concen-
tration of 1.2 1iM. The kinetic studies of
the inhibition showed that the inhibition
ofthe enzyme by coumestrol was competi-
tivewith N9 nM.
The effects of dietary estrogens on the
oxidoreductase activity of MCF-7 cells
which do not contain the placental form of
the 17g-estradiol oxidoreductase (23), was
assessed by determining the conversion of
3H-estr~one (2 nM) to H-estradiol during
the 37 C incubation for 4 to 24 hr. The
reduction of3H-estrone was linear up to 8
hr after the addition of the substrate (Fig.
7). Thereafter, the rate ofreduction result-
ing in the formation of 3H-estradiol
decreased and the ratio of estradiol to
estrone changed little. Neither coumestrol
nor genistein had a significant effect on the
conversion of3H-estrone and 3H-estradiol
in MCF-7 cell cultures at the concentra-
tion of 1.2 pM (Fig. 7). Zearalenone
inhibited the reduction of3H-estrone at 4
to 8 hr after the start of3H-estrone addi-
tion (Fig. 7). At 24 hr, the 3H-estradiol
accumulation had reached the control
level, i.e., the level found in cells cultured
without phytoestrogens. In contrast to the
findings in MCF-7 cells, coumestrol and
genistein both inhibited the reduction of
estrone to 17f3-estradiol in T-47D breast
cancer cells which contain a similar form
ofthe enzyme as found in the human pla-
centa (Fig. 8). Zearalenone had no effect
on the conversion at any tested concentra-
tion.
To determine if inhibition of estrone
conversion to 17f3-estradiol by coumestrol
and genistein in T-47D cells could effect
an estrogen-induced physiological
response, cell proliferation ofthe ER-posi-
tive breast cancer cells was analyzed. The
effects of the phytoestrogens coumestrol
and genistein, alone or cotreatments with
the estrogen agonist estrone, on the prolif-
eration ofT-47D cells are shown in Figure
9. Both coumestrol and genistein stimulat-
ed the proliferation ofthe T-47D cells at 1
pM and 1 nM concentrations, showing
agonist activity. Similarly with the MCF-7
proliferation data, antiestrogenicity was
not shown, since coumestrol and genistein
had an additive effect with estrone. With 1
pM estrone, which is the lowest concentra-
tion giving significant stimulation of pro-
liferation, neither compound inhibited the
stimulatoryeffect ofestrone.
Discussion
Coumestrol, genistein, zearalenone, zeranol,
and biochanin A acted as estrogen agonists
in transiently transfected HeLa cells, with
zearalenone and zeranol showing potent
estrogenic activities. This transcriptional
activation ofCAT was blocked by the pure
estrogen antagonist ICI 164,384 and CAT
induction did not occur in HeLa cells not
transfected with the ER. Therefore, these
dietary estrogens function as transcriptional
activators through ER-mediated mecha-
nisms. Theyhave also been shown to exhib-
it agonist activity in mouse L cells transfect-
ed with a similar CAT reporter gene con-
struct (5), although ERdependence was not
demonstrated in thisstudy.
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Figure 7. Effect of dietary estrogens on the con-
version of estrone to estradiol in MCF-7 cells.
Culture dishes were preincubated with dietary
estrogens for 1 hr. Thereafter, 31-estrone was
added to the incubation medium to give the final
concentration of 0.72 pM. Incubation was contin-
ued for 4 hr and stopped by adding cold carriers
(17I-estradiol and estrone). Steroids were
extracted and analyzed by HPLC as explained in
Materials and Methods. Relative velocities were
calculated for each compound. Values are the
means ± SD from 3-10 dishes. OSE, organic sol-
vent extract.
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Figure 8. Effect of dietary estrogens on the con-
version of estrone to estradiol in T-47D cells.
Culture dishes were preincubated with dietary
estrogens for 1 hr. Thereafter, 3H-estrone was
added to the incubation medium to give the final
concentration of 0.72 pM. Incubation was contin-
ued for 4 hr and stopped by adding cold carriers
(17w-estradiol and estrone). Steroids were
extracted and analyzed by HPLC as explained in
Materials and Methods. Relative velocities were
calculated for each compound. Values are the
means ± SD from 3-10 dishes. OSE, organic sol-
vent extract.
In accordance with the transfection
results in HeLacells, cournestrol, genistein,
biochanin A, zearalenone, and zeranol all
acted as agonist and increased the prolifer-
ation rates ofMCF-7 breast cancer cells in
the absence of endogenous estrogens.
Cournestrol, zearalenone, and zeranol were
also shown to increase the expression ofthe
estrogen-responsive gene, pS2. Cournes-
trol, zearalenone and zeranol were active at
10 pM (in terms ofcell proliferation rate)
while higher concentrations (I100 nM)
wexreag needed. to% showtx the' activity ofrgenis-
tein and biochanin A. These concentra-
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tions are similar to those published earlier
for the activity of these compounds in
MCF-7 cells (4,5). In ourstudy, the lowest
effective dose tested to elicit an estrogen
response could be ranked in the following
order: biochanin A < genistein < coumne-
strol < zeranol = zearalenone < estradiol.
We believe the lowest effective dose to be
the most significant method to rank these
compounds, since high concentrations of
the dietary estrogens, such as concentra-
tions above the maximal 1.2 jiM concen-
tration used in this study, may exert bio-
logical effects through mechanisms other
than directly with the ER. For example, at
high concentrations, genistein is a potent
growth inhibitor of both ER positive and
negative breast cancer cells (6). Isoflavo-
noids, particularly genistein, are also
potent inhibitors of the tyrosine protein
kinase activity of several growth factor
receptors and oncogenes, which may be
associated with tumor cell growth (7,10).
Genistein has also been reported to inhibit
angiogenesis in vitro (11), to stimulate sex
hormone binding globulin formation and
suppress cell proliferation of human hepa-
tocarcinoma cells (12). To show these
effects, high concentrations are required.
The findings of this study clearly indicate
that, at lower concentrations (less than 1
pM), these nonsteroidal compounds,
coumestrol, genistein, and zearalenone,
which represent three structurally different
classes, all act in a similar ER-mediated
mechanism as endogenous estrogens.
None of the compounds showed any
antiestrogenicity in the presence of 17f-
estradiol at an agonist concentration giving
maximal or submaximal stimulation ofcell
proliferation. This suggests that they do
not act as antiestrogens in breast cancer
cells at the concentrations of 10 nM or
below. There are at least two possible
explanations for these findings. First,
because there is a lower binding affinity by
the receptor for the environmental com-
pounds, they are not able to compete, at
the doses tested, with 17g-estradiol for the
receptor ligand binding sites. Second,
binding to the receptor may displace 179-
estradiol from the receptor sites, but the
binding of nonsteroidal estrogen would
also trigger the estrogen action seen as an
increased rate of cell proliferation. At pre-
sent, there is no way to differentiate
between these two possibilities; however,
considering the lower biological activity of
some of these compounds, they might be
expected to show some attenuation of the
proliferative response.
The interconversion of estrone and
17f3-estradiol and formation of their bio-
logically inactive derivatives have a poten-
tially important role in the regulation of
estrogen action at defined sites in the
organism (13). Coumestrol was a remark-
ably good competitive inhibitor of 179-
reduction of estrone when the estrogen-
specific enzyme purified from human pla-
centa was tested (Table 1). The other com-
pounds (genistein, biochanin A, and zear-
alenone) were weaker inhibitors or were
inactive. This means that the structural
requirements for the binding to the ligand
site on the ER differ significantly from the
substrate active site on the estrogen-specific
17f-oxidoreductase enzyme. In the case of
zearalenone, the difference was most strik-
ing. Zearalenone was a potent estrogen,
but was not able to inhibit the conversion
of3H-estrone to 3H-estradiol by the puri-
fied 179-hydroxysteroid oxidoreductase
enzyme. In contrast to the results with the
placental 17t-estradiol oxidoreductase
enzyme, the conversion of 3H-estrone to
3H-estradiol in MCF-7 cells was not inhib-
ited by coumestrol or genistein, while the
conversion was slightly inhibited by zear-
alenone. The obvious explanation would
be the structural properties for the
inhibitor required by the different forms of
the enzyme.
There is evidence for the presence of
multiple forms of 17f3-hydroxysteroid oxi-
doreductase enzyme in breast cancer cells
(13). The placental form ofthe enzyme has
not been found in MCF-7 cells, but T-
47D cells are known to have this form
(23). The proliferative response of the T-
47D cells to estrone occurs at much lower
concentrations than MCF-7 cells, which
may be explained by the more effective
conversion of estrone to estradiol due to
the higher concentration of the oxidore-
ductase enzyme in the T-47D cells.
However, we were not able to show
estrone antagonism (antiestrogenicity) with
the phytoestrogens because theywere effec-
tive at stimulating cell proliferation, pre-
sumably by direct, agonist regulation of
estrogen-responsive genes; this effect may
mask the inhibitory effect on estone activa-
tion ofproliferation. Whether the enzyme
inhibition would play a role in other in
vivo conditions cannot be judged by these
results. Generally, the most abundant cir-
culating endogenous estrogen is estrone,
and this enzyme inhibition may be impor-
tant in tissues which have this enzyme (pla-
centa, breast, endometrium, prostatic ure-
thra, and collecting ducts).
The relevance of all these in vitro find-
ings for the in vivo conditions remains
unclear. There is little information on the
possible action of dietary estrogens in the
human population. In a recent study of
postmenopausal women, plant foods were
found to have significant estrogenlike effect
on vaginal cell maturation, which is a sensi-
tive and specific indicator of estrogenicity
(24). There is no evidence, to date, for their
antiestrogenicity in women. In agreement
with this, we found no evidence to support
the hypothesis that dietary estrogens act as
antiestrogens through competition for the
binding sites of ER or through a metabolic
step involving the inhibition of the inter-
conversion ofestrone to 17g-estradiol, since
this effect could be counteracted by their
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ability to act as an estrogen agonist and
stimlate a biological response. Furthermore,
we conclude that all of these compounds
can act as agonists to induce endogenous
estrogen-specific responses or to transacti-
vate an exogenous estrogen-responsive re-
porter construct by acting directly through
the ER.
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